HAYWARD, Calif.--(BUSINESS WIRE)--IMPAX Laboratories, Inc. (OTC:IPXL) (“IMPAX” or “the Company”) announced today that it has settled its patent litigation suit with Biovail Laboratories International SRL related to IMPAX’s version of Bupropion Hydrochloride Extended-Release Tablets, generic of Wellbutrin® XL, 150 mg and 300 mg. The settlement was made pursuant to an agreement among the Company, Biovail, a subsidiary of Teva Pharmaceutical Industries Ltd., and Anchen Pharmaceuticals.
